<img src="https://ml.globenewswire.com/Resource/Download/00697d05-bd34-4570-822b-f204caf21694?size=2" nborder="0" align="left" hspace="5" vspace="5" title="ogsk2sgeyptxenjnnf5a.png" alt="Orchestra BioMed Holdings, Inc."/>NEW HOPE, Pa., Aug. 27, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day. About Orchestra BioMed Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit <a href="https://www.globenewswire.com/Tracker?data=58nifcRyHyCnsstxSQoox_2J9gplRV1dmrfhwBJ_Gu88hJiIo0-UkziR9XFJsHk0jFC_s_UG2EPJywwde_x9HCelOAWsZ7gjqm7CbESYYQKvT778YpFq4gi3lnkm31KuYMkLhTQwiUkQLv3ZstxvTsY7VNZ2XsQxGdwixL1GhnB5WBdct0sfZwnWI7_2f4R2Vh73fup-kRveenUmGNo0YDRfBF_vIxFI92HseZmO5pN6zoq-yg8fQcoB_2X8N-to8X_tFn6bh5V--8721uQp_Q==" rel="nofollow" target="_blank" title="www.orchestrabiomed.com">www.orchestrabiomed.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=nn-QYuiCMUYaMxFH4qdedMb0UCVzSg4lGPw6HgSqUij0wZOe2cjKTlHs7hUg8colkm1SLWLB1oiwG_XMQEnABoUJnC-ylmJ4DoQ2lCEas3uVc--9bQECk_h4ypi6ck4QPoD59YFIxlXtWblFFMqwcyiH-z-sIr1Sl-tvkuWOX3BDL55NkKBaKihNnVNCOCIKmjT9edG_g4I_nVornWQ9_BZZF1sN0CrgxSnpaTHxZZr6eGp7XMxOwnvrFOaCYazuwcExtnflWJCN9KTE7ZRwHABUZvqRXEfuks6AE8cLZl_qlbw8HcOF49tmwWvdX3Fd" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>. Investor Contact: Silas Newcomb Orchestra BioMed <a href="https://www.globenewswire.com/Tracker?data=wBHM8ZP1JkCV0LSWWZlrttICnk2aeiUp7rKBuuM8j5_nAKjvE61WAvC7E9qYpvcDd4pnYFlLO8u0O-J-bC7fldEqWUUpDzOWGQrNdLOXKSWH8P5fNofsHG8BvPTPa8J8" rel="nofollow" target="_blank" title="snewcomb@orchestrabiomed.com">snewcomb@orchestrabiomed.com</a> Media Contact: Nina Premutico Orchestra BioMed <a href="https://www.globenewswire.com/Tracker?data=-YGEb02agvdxfFxjFUGbfOCxFpFeK7p3mXtTLcCoN9NeR-ZbEVGMcmPBLZh9p0dDUgoYylSAT6_sX5EcDV1A-aLrictHYAzvCc-7TlyMBkcEZ1n9D8YXLvXFi8ZE6rb3" rel="nofollow" target="_blank" title="npremutico@orchestrabiomed.com">npremutico@orchestrabiomed.com</a> <img alt="" src='https://ml.globenewswire.com/media/MGYwOWE3YzctMjUzMS00NjM5LTkzOGEtOGQzNDRhYmVkN2NmLTEyMDU1NzItMjAyNi0wOC0yNy1lbg==/tiny/Orchestra-BioMed-Holdings-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn